AtherosclerosisCell BiologyPeer-reviewed journal article
The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretion
Grigorios PanteloglouiD, Jérôme RobertiD, Marieke SmitiD, Nicolette HuijkmaniD, Niels KloosterhuisiD, Christopher S. LawiD, Brian WoodsiD, Alaa OthmaniD, Marcus Edi KleberiD, Graciela Delgado, Patrizia TarugiiD, Museer A. LoneiD, Justina Clarinda WoltersiD, Antoine RimbertiD, Anja KerksiekiD, D. Luetjohann, Lucia RohreriD, Paolo ZanoniiD, Sofia KakavaiD, Stephanie Haeusler, Eveline SchlumpfiD, Marta FutemaiD, Steve Eric HumphriesiD, Janet S. ChouiD, Winfried Maerz, , Arnold von EckardsteiniD
Abstract
BackgroundDecreased hepatic removal of low density lipoproteins (LDL) and increased apolipoprotein B (apoB) production cause hypercholesterolemia, a major causal risk factor of atherosclerotic cardiovascular disease (ASCVD). By a genome-wide siRNA screen, we previously identified subunits of the Coat protein I (COPI) complex to limit LDL uptake into Huh-7 hepatocarcinoma cells. MethodsThese findings were validated by targeted in vitro experiments as well as genetic association studies in humans and three mouse models with mutated or disrupted COPI genes. ResultsSilencing of COPA, COPB1, COPB2, ARCN1, COPG1, and COPZ1 in Huh-7 cells resulted in decreased uptake of LDL and aberrant glycosylation and altered cell surface abundance of the LDL receptor (LDLR) as well as increased apoB secretion and cellular lipid storage. Single nucleotide polymorphisms of ARCN1 were associated with lower ARCN1 expression and higher levels of LDL-cholesterol (LDL-C). Rare variants of COPA and COPG1 were enriched among patients with LDL-C > 5 mmol/L. Patients and mice carrying other rare immunopathogenic missense variants of COPA and COPG1 did not present with elevated plasma levels of LDL-C, while hepatic knockdown of murine Copg1 increased the concentrations of non-HDL-cholesterol in plasma and triglycerides in the liver. ConclusionsThe COPI coatomer regulates LDLR activity and apoB secretion as well as lipid content of liver cells. Loss of function of some variants of COPI genes are associated with higher LDL-C levels.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- approach: genetic perturbation / CRISPR
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 40th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hepatic Inactivation of Carnitine Palmitoyltransferase 1a Lowers Apolipoprotein B Containing Lipoproteins in Mice
Robert Nathaniel Helsley, Mikala M. Zelows, … Gregory A. Graf·Arteriosclerosis Thrombosis and Vascular BiologyPeer-reviewed·Jun 12, 2025
- GOLIATH regulates LDLR availability and plasma LDL cholesterol levels
Bethan L. Clifford, Kelsey E. Jarrett, … Elizabeth J. Tarling·bioRxiv·Dec 9, 2020
- Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult
S. Hellberg, O. Ahmed, … S. G. Malin·bioRxiv·Oct 13, 2022
- Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening
Taslima Gani Khan, Juliana Bragazzi Cunha, … Brian T. Emmer·AtherosclerosisPeer-reviewed·Mar 22, 2025
- Lzp Ablation Ameliorates Dyslipidemia and Suppresses Atherosclerosis by Reducing Circulating Apolipoprotein B-Containing Lipoproteins
Kunyan He, Xin Ku, … Ze‐Guang Han·bioRxiv·Sep 24, 2025
- Regulation of cellular LDL uptake by PROX1 and CHD7
Candilianne Serrano-Zayas, Matthew L. Holding, … Brian T. Emmer·bioRxiv·Sep 20, 2022